Skip to main content
Schott Pharma logo

Schott Pharma — Investor Relations & Filings

Ticker · 1SXP ISIN · DE000A3ENQ51 LEI · 529900TU48UE99NHEY88 F Manufacturing
Open in API
Filings indexed 134 across all filing types
Latest filing 2024-04-30 Board/Management Inform…
Country DE Germany
Listing F 1SXP

About Schott Pharma

https://www.schott-pharma.com/en

Schott Pharma is a developer and manufacturer of drug containment solutions and delivery systems for injectable drugs. Serving the pharmaceutical and biotech industries, its portfolio includes prefillable syringes, cartridges, vials, and ampoules. The company provides scientifically proven products designed for the safe storage and administration of medications. Beyond individual components, Schott Pharma offers complete, compatible systems and a range of services, including analytical, development, fill-and-finish, and regulatory support. This integrated approach supports clients from clinical trials through to commercialization, ensuring compatibility across the entire pharma value chain.

Recent filings

Filing Released Lang Actions
SCHOTT Pharma appoints Tobias Erfurth as Head of Investor Relations
Board/Management Information Classification · 1% confidence The document is a news release announcing a personnel change: the appointment of Tobias Erfurth as the new Head of Investor Relations. It uses the standard format for corporate news dissemination (EQS-News) and focuses entirely on management structure changes, specifically within the Investor Relations function. This aligns directly with the definition for Board/Management Information (MANG), which covers announcements of changes in senior management.
2024-04-30 English
SCHOTT Pharma to Expand in the U.S. with New Prefillable Syringe Manufacturing Facility
Regulatory Filings Classification · 1% confidence The document is a news release titled "SCHOTT Pharma to Expand in the U.S. with New Prefillable Syringe Manufacturing Facility" and is explicitly marked as an 'EQS-News'. It details a strategic company decision involving a significant capital investment ($371 million) and job creation related to expanding manufacturing capacity. This type of announcement, focusing on strategic corporate decisions, expansion plans, and capital expenditure, fits best under the 'Capital/Financing Update' (CAP) category if it were purely about raising funds, or 'Regulatory Filings' (RNS) if it were a general announcement. However, since it details a major strategic investment and expansion, it is a significant corporate event announcement. Given the options, it is not a formal financial report (10-K, IR, ER), nor a management change (MANG), nor a shareholder vote result (DVA). It is a major strategic corporate announcement regarding investment and expansion. While 'CAP' covers financing activities, this is more about operational expansion funded by internal/existing capital structure, making it a general corporate news item. Since it is a formal announcement disseminated via a news service (EQS-News) detailing a major strategic move that isn't covered by the more specific financial report codes, the most appropriate general category for significant, non-standard corporate news is 'Regulatory Filings' (RNS), which serves as a broad category for important corporate disclosures that don't fit elsewhere, or potentially 'CAP' if the investment is viewed as a major capital deployment. Given the focus on a 'Strategic Company Decision/Expansion' rather than a specific financing round, RNS is the safer fallback for a major corporate news release that isn't a standard periodic report.
2024-03-18 English
Vergütungsbericht 2022/2023
Remuneration Information Classification · 1% confidence The document is explicitly titled "VERGÜTUNGSBERICHT FÜR DAS GESCHÄFTSJAHR 2022/2023" (Remuneration Report for the Fiscal Year 2022/2023). It details the granted and accrued compensation for board members and supervisory board members, referencing German corporate law (§ 162 Abs. 1 AktG) and the German Corporate Governance Code (DCGK). This content directly corresponds to the definition of a Remuneration Information report, which maps to the code DEF 14A (Proxy Solicitation & Information Statement, often used for compensation disclosures in the US context, but here matching the specific German content type related to executive pay disclosure). Although the German term is 'Vergütungsbericht', among the provided codes, 'DEF 14A' is the closest match as it specifically relates to executive compensation disclosure, which is the primary subject matter of this document. The document is a full report, not an announcement of a report (RPA/RNS), and its length (47,144 chars) confirms it is a comprehensive disclosure.
2024-03-15 German
Remuneration Report 2022/2023
Remuneration Information Classification · 1% confidence The document is explicitly titled "REMUNERATION REPORT FOR FISCAL YEAR 2022/2023". It details the remuneration granted and owed to the members of the Management Board and Supervisory Boards, referencing regulatory requirements like section 162(1) of the AktG (German Stock Corporation Act) and the German Corporate Governance Code (GCGC). This content directly aligns with the definition of a Remuneration Information document, which corresponds to the filing code DEF 14A (Proxy Solicitation & Information Statement often includes remuneration details, but the specific definition provided for DEF 14A is 'Report detailing compensation for top executives and directors'). Given the explicit focus on remuneration details, DEF 14A is the most appropriate classification, even though the document structure might resemble other detailed reports.
2024-03-15 English
Successful 2024 Annual General Meeting of SCHOTT Pharma: Shareholders approve all items on the agenda
AGM Information Classification · 1% confidence The document explicitly discusses the 'Successful 2024 Annual General Meeting of SCHOTT Pharma' and details the voting results for various agenda items, including the adoption of financial statements and dividend approval. The key phrase is 'Annual General Meeting' and the content focuses entirely on the proceedings and outcomes of this meeting. This directly corresponds to the definition of AGM Information (AGM-R). It is not a full 10-K, an earnings release (ER), or a proxy statement (PSI), but rather a report on the meeting itself.
2024-03-14 English
Remuneration System for the Members of the Supervisory Board
Remuneration Information Classification · 1% confidence The document details the remuneration system for the Supervisory Board of SCHOTT Pharma AG & Co. KGaA, including fixed remuneration amounts, committee compensation, and the process for determining and reviewing this compensation. This content specifically addresses executive and board compensation policies, which aligns with the definition for 'Remuneration Information' (DEF 14A).
2024-03-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.